U.S. markets closed
  • S&P Futures

    4,137.50
    +9.75 (+0.24%)
     
  • Dow Futures

    33,768.00
    +59.00 (+0.18%)
     
  • Nasdaq Futures

    13,784.00
    +33.75 (+0.25%)
     
  • Russell 2000 Futures

    2,245.50
    +17.20 (+0.77%)
     
  • Crude Oil

    61.81
    +0.38 (+0.62%)
     
  • Gold

    1,787.20
    +5.20 (+0.29%)
     
  • Silver

    26.22
    +0.04 (+0.15%)
     
  • EUR/USD

    1.2026
    +0.0009 (+0.07%)
     
  • 10-Yr Bond

    1.5540
    -0.0100 (-0.64%)
     
  • Vix

    18.71
    +1.21 (+6.91%)
     
  • GBP/USD

    1.3859
    +0.0016 (+0.12%)
     
  • USD/JPY

    107.9260
    -0.0340 (-0.03%)
     
  • BTC-USD

    50,087.50
    -3,450.57 (-6.45%)
     
  • CMC Crypto 200

    1,138.89
    -104.17 (-8.38%)
     
  • FTSE 100

    6,938.24
    +42.95 (+0.62%)
     
  • Nikkei 225

    28,983.31
    -204.86 (-0.70%)
     

AstraZeneca/Amgen's Tezepelumab Reduces Asthma Exacerbations, Phase 3 Trial Shows

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • AstraZeneca Plc (NASDAQ: AZN) and its partner Amgen Inc (NASDAQ: AMGN) have announced positive results from NAVIGATOR Phase 3 trial evaluating tezepelumab in severe asthma.

  • Results were presented at the American Academy of Asthma Allergy & Immunology Annual Meeting.

  • Tezepelumab achieved a 56% reduction in exacerbation rate over 52 weeks in the overall patient population, compared to placebo when added to standard of care.

  • In a pre-specified analysis of the subgroup of patients with baseline eosinophil counts less than 300 cells per microliter, tezepelumab achieved a 41% reduction in exacerbation rate.

  • 39% and 70% reduction in patients with baseline eosinophil counts less than 150 and greater than or equal to 300 cells per microliter, respectively.

  • No clinically meaningful differences in safety results between the tezepelumab and placebo groups were observed.

  • The most frequently reported adverse events were nasopharyngitis, upper respiratory tract infection, and headache.

  • Tezepelumab blocks the action of thymic stromal lymphopoietin, an epithelial cytokine that plays a key role across the spectrum of asthma inflammation.

  • Price Action: AZN and AMGN shares are down 0.9% in market trading hours on the last check Friday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.